Psychiatric Symptoms Induced by Antiviral Therapy in Chronic Hepatitis C
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Background and objective: Interferon-α treatment is associated with a large number of adverse effects. Depressive symptoms are not unexpected, and potentially dangerous psychiatric adverse effects can induce life-threatening conditions. We compared the incidence of depressive symptoms in patients with chronic hepatitis C during treatment with pegylated interferon-α-2a (IFNα-2a) and pegylated interferon-α-2b (IFNα-2b).
Patients and design: We randomly divided 186 subjects with chronic hepatitis C into two treatment groups: group A, treated with IFNα-2a, and group B, treated with IFNα-2b. Treatment was continued for up to 48 weeks. Liver biopsy and hepatitis C virus RNA assay were carried out in all patients. Depressive symptoms and the prevalence of psychiatric adverse effects during treatment with IFN were evaluated using the Hamilton Depression Rating Scale, the Zung Self-Rating Depression Scale, and the Structured Clinical Interview for Diagnostic and Statistic Manual-IV axis disorders.
Results: At baseline 53% of subjects in group A and 57% of subjects in group B presented with depressive symptoms; at 12 weeks we found a high incidence of depressive symptoms in both groups (group A 61% and group B 65%) and three cases of life-threatening psychiatric symptoms (i.e. psychosis and delirium requiring discontinuation of antiviral therapy and admission to a psychiatric unit) in group A.
Conclusions: Long-term administration of IFN can be associated with serious psychiatric adverse effects. It is very important that psychiatric symptoms are diagnosed early in IFN treatment so to improve treatment compliance and prevent fatal and/or life-threatening adverse events, as were documented in some subjects treated with IFNα-2a in our study.
- Foster GR. Pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20: 825–30 CrossRef
- First Annual meeting of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 2006; 1: S56-9
- Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha Interferon. J Hepatol 1996; 24: 38–47 CrossRef
- Scalori A, Pozzi M, Bellia V, et al. Interferon-induced depression: prevalence and management. Dig Liver Dis 2005; 37: 102–7 CrossRef
- Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72: 237–41 CrossRef
- Dieperink E, Ho SB, Tetrick L, et al. Suicidal ideation during interferon-alpha 2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psych 2004; 26: 237–40 CrossRef
- Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 4315 CrossRef
- DSM IV-TR: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Arlington (VA): American Psychiatric Association, 2000
- Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62 CrossRef
- Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63–70 CrossRef
- Steinberg M. Structured Clinical Interview for DSM-IV axis disorders. Arlington (VA): American Psychiatric Association, 1994
- Malaguarnera M, Di Fazio I, Restuccia S, et al. Interferon alpha induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychology 1998; 37: 93–7
- Diepering E, Willebring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157: 867–76 CrossRef
- Madday WC. Safety of combination interferon alpha-2b/ribavirin therapy on chronic hepatitis C-relapsed and treatment-naïve patients. Semin Liver Dis 1999; 19Suppl. 1: 67–75
- Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999; 461: 25–46 CrossRef
- Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004; 82: 175–90 CrossRef
- Juengling FD, Ebert D, Gut O, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 2000; 152: 383–9 CrossRef
- Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002; 347: 975–82 CrossRef
- Manns MP, McHutchison JG, Gordon SC, et al. Pegintron alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–65 CrossRef
- Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Pegintron alpha 2-a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 436–55
- Zeuzem S, Diago M, Gane E, et al. Peginterferon alpha-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724–32 CrossRef
- Kraus MR, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alpha-2b therapy. Psychiatry 2003; 64: 708–14
- Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C. Hepatology 2002; 36Suppl. 5: S1–2 CrossRef
- Psychiatric Symptoms Induced by Antiviral Therapy in Chronic Hepatitis C
Clinical Drug Investigation
Volume 26, Issue 11 , pp 655-662
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors